Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | HINT1 | P49773 | 4/20 | 0.68 |
| ▸ | NT5E | P21589 | 2/20 | 0.68 |
| ▸ | PNP | P00491 | 1/20 | 0.65 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.65 |
| ▸ | GSK3A | P49840 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.64 |
| ▸ | TGM2 | P21980 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanosine SCHEMBL8593215 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL531207 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL413586 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049416 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL11986902 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049608 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049417 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049467 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL20750695 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL16800938 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1951 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120060108-A | Method for high-yield phenazine-1-carboxamide by utilizing pseudomonas | 齐鲁工业大学(山东省科学院) | 2025-05-30 | — | — | CN | claimed |
| US-20250171815-A1 | PRODUCTION OF PSYCHEDELIC COMPOUNDS | CORE ONE LABS INC (CA) | 2025-05-29 | — | — | US | claimed |
| WO-2025090773-A1 | ASSESSMENT OF SYSTEMIC IMMUNITY USING [F18]F-Ara-G IN POSITRON EMISSION TOMOGRAPHY | CELLSIGHT TECHNOLOGIES INC. (US) | 2025-05-01 | — | — | WO | claimed |
| US-12157766-B2 | Cytoplasmic expression system | Absci Corporation (US) | 2024-12-03 | — | — | US | claimed |
| EP-4463556-A1 | PRODUCTION OF PSYCHEDELIC COMPOUNDS | Core One Labs Inc. (CA) | 2024-11-20 | — | — | EP | claimed |
| CN-117778499-A | Method for producing arabinonucleoside by biocatalysis | 河南师范大学 | 2024-03-29 | — | — | CN | claimed |
| EP-4273257-A2 | INDUCIBLE COEXPRESSION SYSTEM | ABSCI Corporation (US) | 2023-11-08 | — | — | EP | claimed |
| CN-116479075-A | Method for preparing arabinoside through enzyme catalysis | 河南师范大学 | 2023-07-25 | — | — | CN | claimed |
| WO-2023130191-A1 | PRODUCTION OF PSYCHEDELIC COMPOUNDS | CORE ONE LABS INC. (CA) | 2023-07-13 | — | — | WO | claimed |
| CN-116298235-A | Serum metabolism biomarker for diagnosing or monitoring breast cancer and screening method thereof | 哈尔滨医科大学 | 2023-06-23 | — | — | CN | claimed |
| EP-1283874-A2 | NOVEL DEOXYNUCLEOSIDE KINASE ENZYME VARIANTS | Knecht, Wolfgang (DK) | 2003-02-19 | — | — | EP | claimed |
| WO-2002057425-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | claimed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | claimed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2001088106-A2 | NOVEL DEOXYRIBONUCLESIDE KINASE ENZYME MULTI-SUBSTRATE VARIANTS | KNECHT WOLFGANG (DK) | 2001-11-22 | — | — | WO | claimed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | claimed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| EP-0549615-A4 | SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 1997-08-27 | — | — | EP | claimed |
| EP-0549615-A1 | SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1993-07-07 | — | — | EP | claimed |
| WO-1992003568-A1 | SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1992-03-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | HPGD 3661/4885HINT1 2929/4885NT5E 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.